Literature DB >> 22518272

New considerations in the design of clinical trials for traumatic brain injury.

Bob Roozenbeek1, Hester F Lingsma, Andrew Ir Maas.   

Abstract

Randomized controlled trials in traumatic brain injury (TBI) pose several complicated methodological challenges related to the heterogeneity of the population. Several strategies have been proposed to deal with these challenges. Recommendations presented by the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) study group include the use of relatively broad enrollment criteria combined with covariate adjustment for strong predictors of outcome in the analysis phase, rather than the use of strict enrollment criteria. Furthermore, an ordinal rather than a dichotomized analysis of the Glasgow Outcome Scale - the outcome measure in most TBI trials - will increase the statistical power significantly. This review discusses the issue of heterogeneity in TBI trials and summarizes the value of different innovative methods for the design and statistical analysis of randomized controlled trials in TBI. Future directions highlight the opportunities offered by alternative strategies, such as comparative effectiveness research, to investigate the clinical benefits of established and novel therapies in TBI.

Entities:  

Year:  2012        PMID: 22518272      PMCID: PMC3326520          DOI: 10.4155/cli.11.179

Source DB:  PubMed          Journal:  Clin Investig (Lond)        ISSN: 2041-6792


  44 in total

1.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

Review 2.  Critical appraisal of neuroprotection trials in head injury: what have we learned?

Authors:  Christos M Tolias; M Ross Bullock
Journal:  NeuroRx       Date:  2004-01

3.  A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project.

Authors:  Gillian S McHugh; Isabella Butcher; Ewout W Steyerberg; Anthony Marmarou; Juan Lu; Hester F Lingsma; James Weir; Andrew I R Maas; Gordon D Murray
Journal:  Clin Trials       Date:  2010-02       Impact factor: 2.486

4.  Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations

Authors: 
Journal:  Neurosurgery       Date:  1999-06       Impact factor: 4.654

5.  Decompressive craniectomy in diffuse traumatic brain injury.

Authors:  D James Cooper; Jeffrey V Rosenfeld; Lynnette Murray; Yaseen M Arabi; Andrew R Davies; Paul D'Urso; Thomas Kossmann; Jennie Ponsford; Ian Seppelt; Peter Reilly; Rory Wolfe
Journal:  N Engl J Med       Date:  2011-03-25       Impact factor: 91.245

6.  The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial.

Authors:  Heleen M den Hertog; H Bart van der Worp; H Maarten A van Gemert; Ale Algra; L Jaap Kappelle; Jan van Gijn; Peter J Koudstaal; Diederik W J Dippel
Journal:  Lancet Neurol       Date:  2009-03-16       Impact factor: 44.182

7.  External validation of the international mission for prognosis and analysis of clinical trials model and the role of markers of coagulation.

Authors:  Rahul Raj; Jari Siironen; Riku Kivisaari; Juha Hernesniemi; Päivi Tanskanen; Lauri Handolin; Markus B Skrifvars
Journal:  Neurosurgery       Date:  2013-08       Impact factor: 4.654

8.  NXY-059 for acute ischemic stroke.

Authors:  Kennedy R Lees; Justin A Zivin; Tim Ashwood; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; James Grotta; Patrick Lyden; Ashfaq Shuaib; Hans-Göran Hårdemark; Warren W Wasiewski
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

9.  The added value of ordinal analysis in clinical trials: an example in traumatic brain injury.

Authors:  Bob Roozenbeek; Hester F Lingsma; Pablo Perel; Phil Edwards; Ian Roberts; Gordon D Murray; Andrew Ir Maas; Ewout W Steyerberg
Journal:  Crit Care       Date:  2011-05-17       Impact factor: 9.097

10.  Predicting outcome after traumatic brain injury: development and international validation of prognostic scores based on admission characteristics.

Authors:  Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas
Journal:  PLoS Med       Date:  2008-08-05       Impact factor: 11.069

View more
  16 in total

Review 1.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

Review 2.  Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury.

Authors:  Meghan O Blaya; Joseph M Wasserman; Andrew A Pieper; Thomas J Sick; Helen M Bramlett; W Dalton Dietrich
Journal:  Neuropharmacology       Date:  2018-09-17       Impact factor: 5.250

Review 3.  Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury?

Authors:  Kyle R Gronbeck; Cecilia M P Rodrigues; Javad Mahmoudi; Eric M Bershad; Geoffrey Ling; Salam P Bachour; Afshin A Divani
Journal:  Neurocrit Care       Date:  2016-08       Impact factor: 3.210

4.  Neuroprotective Efficacy of a Sigma 2 Receptor/TMEM97 Modulator (DKR-1677) after Traumatic Brain Injury.

Authors:  Edwin Vázquez-Rosa; Michael R Watson; James J Sahn; Timothy R Hodges; Rachel E Schroeder; Coral J Cintrón-Pérez; Min-Kyoo Shin; Terry C Yin; Josie L Emery; Stephen F Martin; Daniel J Liebl; Andrew A Pieper
Journal:  ACS Chem Neurosci       Date:  2018-12-03       Impact factor: 4.418

Review 5.  Alternative clinical trial design in neurocritical care.

Authors:  Christos Lazaridis; Andrew I R Maas; Michael J Souter; Renee H Martin; Randal M Chesnut; Stacia M DeSantis; Gene Sung; Peter D Leroux; Jose I Suarez
Journal:  Neurocrit Care       Date:  2015-06       Impact factor: 3.210

Review 6.  A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury.

Authors:  Peter Bragge; Anneliese Synnot; Andrew I Maas; David K Menon; D James Cooper; Jeffrey V Rosenfeld; Russell L Gruen
Journal:  J Neurotrauma       Date:  2016-03-18       Impact factor: 5.269

7.  Haptoglobin genotype and aneurysmal subarachnoid hemorrhage: Individual patient data analysis.

Authors:  Ben Gaastra; Dianxu Ren; Sheila Alexander; Ellen R Bennett; Dawn M Bielawski; Spiros L Blackburn; Mark K Borsody; Sylvain Doré; James Galea; Patrick Garland; Tian He; Koji Iihara; Yoichiro Kawamura; Jenna L Leclerc; James F Meschia; Michael A Pizzi; Rafael J Tamargo; Wuyang Yang; Paul A Nyquist; Diederik O Bulters; Ian Galea
Journal:  Neurology       Date:  2019-04-05       Impact factor: 9.910

8.  Longitudinal Changes in Disability Rating Scale Scores: A Secondary Analysis Among Patients With Severe TBI Enrolled in the Epo Clinical Trial.

Authors:  Julia S Benoit; H Julia Hannay; Jose-Miguel Yamal; David J Francis; Imoigele Aisiku; Claudia Robertson
Journal:  J Int Neuropsychol Soc       Date:  2019-03       Impact factor: 2.892

Review 9.  Early to Long-Term Alterations of CNS Barriers After Traumatic Brain Injury: Considerations for Drug Development.

Authors:  Beatriz Rodriguez-Grande; Aleksandra Ichkova; Sighild Lemarchant; Jerome Badaut
Journal:  AAPS J       Date:  2017-09-13       Impact factor: 4.009

Review 10.  Optimizing Outcome Assessment in Multicenter TBI Trials: Perspectives From TRACK-TBI and the TBI Endpoints Development Initiative.

Authors:  Yelena G Bodien; Michael McCrea; Sureyya Dikmen; Nancy Temkin; Kim Boase; Joan Machamer; Sabrina R Taylor; Mark Sherer; Harvey Levin; Joel H Kramer; John D Corrigan; Thomas W McAllister; John Whyte; Geoffrey T Manley; Joseph T Giacino
Journal:  J Head Trauma Rehabil       Date:  2018 May/Jun       Impact factor: 2.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.